KRT7

Across TCGA pan-cancer cohorts, KRT7 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KRT7 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher KRT7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRT7 expression acts as an unfavorable survival marker.

BRCA, MESO, and PRAD are the cancer types where KRT7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.165	0.833	<.001	20	view →
MESO	OS	Median	II,III,IV	0.121	0.571	.004	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	IV	0.128	0.483	.001	6	view →
HNSC	DFS	Median	IV	0.184	0.672	.006	3	view →
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KRT7–BRCA (OS)

Open the BRCA breakdown →